Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

NCT01813253 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Cancer

Interventions

DRUG: Irinotecan
DRUG: Nimotuzumab

Sponsor

Kuhnil Pharmaceutical Co., Ltd.

Collaborators

[object Object]